Blockade of IL-6 signaling prevents paclitaxel-induced neuropathy in C57Bl/6 mice

Autor: Wolfgang Boehmerle, Hannah Muenzfeld, Matthias Endres, Petra Huehnchen
Rok vydání: 2020
Předmět:
Male
Cancer Research
metabolism [Interleukin-6]
medicine.medical_treatment
Pharmacology
Neuropathic pain
Calcium in biology
Cohort Studies
chemistry.chemical_compound
pathology [Ganglia
Spinal]

Ganglia
Spinal

metabolism [Nervous System Diseases]
biology
lcsh:Cytology
pathology [Sensory Receptor Cells]
adverse effects [Paclitaxel]
Neurodegeneration
Calpain
Middle Aged
Pathophysiology
Cytokine
Paclitaxel
pharmacology [Antibodies
Neutralizing]

Female
Signal Transduction
drug effects [Signal Transduction]
Sensory Receptor Cells
Immunology
Models
Biological

Article
Cellular and Molecular Neuroscience
Neurotoxicity syndromes
ddc:570
medicine
Animals
Humans
lcsh:QH573-671
Chemotherapy
Interleukin-6
business.industry
pharmacology [Paclitaxel]
Cell Biology
medicine.disease
Antibodies
Neutralizing

Rats
Mice
Inbred C57BL

chemically induced [Nervous System Diseases]
Peripheral neuropathy
Animals
Newborn

chemistry
biology.protein
Nervous System Diseases
drug effects [Sensory Receptor Cells]
business
Zdroj: Cell Death & Disease
Cell death & disease 11(1), 45 (2020). doi:10.1038/s41419-020-2239-0
Cell Death and Disease, Vol 11, Iss 1, Pp 1-13 (2020)
ISSN: 2041-4889
DOI: 10.1038/s41419-020-2239-0
Popis: The microtubule-stabilizing agent paclitaxel frequently leads to chemotherapy-induced peripheral neuropathy (CIN), which further increases the burden of disease and often necessitates treatment limitations. The pathophysiology of CIN appears to involve both “upstream” effects including altered intracellular calcium signaling and activation of calcium dependent proteases such as calpain as well as subsequent “downstream” neuro-inflammatory reactions with cytokine release and macrophage infiltration of dorsal root ganglia. In this study, we aimed to investigate whether these processes are linked by the pro-inflammatory cytokine interleukin-6 (IL-6). We observed that paclitaxel exposure induced IL-6 synthesis in cultured sensory neurons from postnatal Wistar rats, which could be prevented by co-treatment with a calpain inhibitor. This suggests a calcium dependent process. We demonstrate that adult C57BL/6 mice deficient in IL-6 are protected from developing functional and histological changes of paclitaxel-induced neuropathy. Furthermore, pretreatment with an IL-6-neutralizing antibody resulted in the prevention of paclitaxel-induced neuropathy in C57BL/6 mice. Electrophysiological data from our preclinical model was adequately reflected by measurements of patients undergoing paclitaxel therapy for ovarian cancer. In this cohort, measured Il-6 levels correlated with the severity of neuropathy. Our findings demonstrate that IL-6 plays a pivotal role in the pathophysiology of paclitaxel-induced neuropathy per se and that pharmacological or genetic interference with this signaling pathway prevents the development of this potentially debilitating adverse effect. These findings provide a rationale for a clinical trial with IL-6 neutralizing antibodies to prevent dose-limiting neurotoxic adverse effects of paclitaxel chemotherapy.
Databáze: OpenAIRE